Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biosciences Inks Alliance for Cloud-based Analysis

NEW YORK (GenomeWeb News) – Pacific Biosciences today said that it has partnered with Cycle Computing to optimize its PacBio RS Single-Molecule Real-Time Analysis software for the cloud.

The Menlo Park, Calif.-based firm said that the cloud-based version of its software would scale to meet the data analysis needs of SMRT sequencing and support a workflow that includes sample preparation, sequencing, and data analysis in less than a single day. PacBio plans to release a beta version of the cloud-based solution with the next major upgrade of its RS, which is scheduled for the end of this year.

"Analysis of long, single-molecule, real-time sequencing reads from unamplified samples without the need to maintain complex and expensive hardware and software will offer customers more flexibility to realize the potential of the PacBio RS," Edwin Hauw, director of software product management for Pacific Biosciences, said in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.